CoChat

Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males

Colao, Annamaria, De Rosa, Michele, Sarnacchiaro, Francesca, Di Sarno, Antonella, Landi, Maria Luisa, Iervolino, Emilia, Zarrilli, Stefano, Merola, Bartolomeo, Lombardi, Gaetano · 1996 · European Journal of Endocrinology
Cited by 45

The DOI matches its Crossref record.

Abstract

Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E, Zarrilli S, Merola B, Lombardi G. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996;135:548–52. ISSN 0804–4643 The aim of this study was to evaluate the effects of a chronic treatment with the non-ergot-derived dopamine agonist quinagolide (CV 205-502) on sexual and gonadal function in hyperprolactinemic males. Thirteen males with macroprolactinoma and one with microprolactinoma were treated with CV 205-502 at the dose of 0.15–0.6 mg/day for 6–24 months. Baseline prolactin (PRL) was 464 ± 75.7 μg/l. All the patients suffered from libido impairment, five of reduced sexual potency, six had infertility and in four bilateral induced galactorrhea was shown. The semen analysis revealed a severe oligoasthenospermia with reduced sperm count, motility and forward progression, with an abnormal morphology and decreased viability. A significant reduction of serum PRL levels (nadir PRL = 12.3 ± 5.4 μg/l) was obtained during the treatment. Normalization of prolactinemia was reached in 13 of the 14 patients after 3 months. After 1 year, a significant improvement of sperm parameters, in terms of increase of number (from 5600 ± 111 to 20 564 ± 587 mm 3), motility at 1 h (from 24.8 ± 0.1 to 52.6 ± 0.5%), forward progression (from 24 ± 1.4 to 62.3 ± 2.9%) and normal morphology (from 53.8 ± 2.5 to 62.2 ± 2.4%), was recorded. In addition, a significant increase of serum follicle-stimulating hormone (from 5.3 ± 0.6 to 7.8 ± 0.4 U/l), luteinizing hormone (from 4.4 ± 0.5 to 7.7 ± 0.4 U/l) and testosterone (from 3.4 ± 0.4 to 4.7 ± 0.2 μg/l) was recorded. A significant increase of luteinizing hormone (9.4 ± 0.7 U/l) and testosterone (5.2 ± 0.4 μg/l), as well as a further improvement of sperm parameters, was found after 2 years of therapy. Sellar computed tomography and/or magnetic resonance showed a considerable shrinkage (⩾ 30%) of tumoral mass in 8 out of 13 patients with macroprolacinoma. Side effects were recorded in only one patient. In conclusion, the treatment with CV 205-502 normalizing PRL levels improves gonadal and sexual function and fertility in males with prolactinoma, providing good tolerability and excellent patient compliance to medical treatment. This result demonstrates that the impairment of gonadal function in hyperprolactinemic patients is a functional modification. Annamaria Colao, Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University, via S. Pansini 5, 80131 Naples, Italy

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje.0.1350548

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 45

Metadata

Authors
Colao, A., De Rosa, M., Sarnacchiaro, F., Di Sarno, A., Landi, M. L., Iervolino, E., Zarrilli, S., Merola, B., & Lombardi, G.
Venue
European Journal of Endocrinology
Published
1996-11
Volume
135
Issue
5
Pages
548-552
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2120096954
Cited by
45
References
0
FWCI
1.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. https://app.cochat.ai/papers/10.1530/eje.0.1350548
The paper
Colao, A., De Rosa, M., Sarnacchiaro, F., Di Sarno, A., Landi, M. L., Iervolino, E., Zarrilli, S., Merola, B., & Lombardi, G. (1996). Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.1350548

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.